24 completed. 24 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Completed 24 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
Follow Breast Neoplasm: new trials by email Literature Review of Breast Neoplasm trials Research Report on Breast Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer trifluridine/tipiracil - Breast Neoplasm, Chemotherapy Effect | Phase 2 | Completed | Borstkanker Onderzoek Groep | 52 | 2020-09-25 | 2026-05-22 |
| Anlotinib in Metastatic HER2 Negative Breast Cancer Anlotinib Hydrochloride - Breast Neoplasm, Antineoplastic Agents | Phase 2 | Completed | Peng Yuan | 26 | 2018-07-12 | 2020-07-29 |
| Combination Study of SV-BR-1-GM With Retifanlimab SV-BR-1-GM, Low dose cyclophosphamide, Interferon Inoculation - Breast Cancer, Breast Neoplasm | Phase 1 / Phase 2 | Completed | BriaCell Therapeutics Corporation | 36 | 2018-03-16 | 2026-03-27 |
| SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer SV-BR-1-GM, Cyclophosphamide, Interferon-alpha-2b - Breastcancer, Breast Neoplasm | Phase 1 / Phase 2 | Completed | BriaCell Therapeutics Corporation | 24 | 2017-05-05 | 2021-01-29 |
| SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer SFX-01, Fulvestrant, Tamoxifen - Breast Neoplasm | Phase 2 | Completed | Evgen Pharma | 60 | 2016-10-01 | 2019-07-12 |
| Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) Eribulin Mesylate, Pembrolizumab - Breast Neoplasm | Phase 1 / Phase 2 | Completed | Eisai Inc. | 258 | 2015-08-28 | 2022-05-05 |
| Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment Eribulin - Breast Neoplasm, Metastasis | Phase 2 | Completed | MedSIR | 53 | 2013-07-01 | 2025-06-08 |
| Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib Pazopanib - Breast Cancer, Breast Neoplasm | Phase 2 | Completed | Hope Rugo, MD | 30 | 2012-04-27 | 2020-07-08 |
| Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer Letrozole (Femara), Letrozole; Avastin - Breast Cancer, Cancer of the Breast | Phase 2 | Completed | University of Alabama at Birmingham | 75 | 2007-10-08 | 2022-10-21 |
| Yoga to Reduce Cancer Fatigue Yoga - Breast Neoplasm | Phase 2 | Completed | University of Iowa | 66 | 2007-08-01 | 2008-12-04 |
| Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048) doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, PLD, cyclophosphamide, trastuzumab, paclitaxel - Breast Neoplasm | Phase 2 | Completed | Merck Sharp & Dohme LLC | 181 | 2007-07-16 | 2017-06-07 |
| Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer cetuximab, cisplatin, cisplatin - Breast Neoplasm | Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 181 | 2007-06-01 | 2014-02-13 |
| Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer Sagopilone (ZK 219477) - Breast Neoplasm | Phase 2 | Completed | Bayer | 65 | 2006-04-01 | 2015-12-10 |
| Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients epirubicin, cyclophosphamide, docetaxel - Breast Neoplasm | Phase 2 | Completed | Accelerated Community Oncology Research Network | 30 | 2005-11-01 | 2012-03-20 |
| A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679) Pegylated Liposomal Doxorubicin, Docetaxel, Trastuzumab - Breast Neoplasm | Phase 2 | Completed | Merck Sharp & Dohme LLC | 27 | 2005-07-15 | 2018-07-03 |
| Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women RAD001, Letrozole 2.5mg, Letrozole 2.5mg - Breast Neoplasm | Phase 2 | Completed | Novartis Pharmaceuticals | 267 | 2005-03-01 | 2013-03-04 |
| Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC Paclitaxel weekly in combination with capecitabine, Docetaxel every 3 week in combination with capecitabine - Breast Neoplasm | Phase 2 / Phase 3 | Completed | Norwegian Breast Cancer Group | 224 | 2005-03-01 | 2008-05-20 |
| A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948) Pegylated Lyposomal Doxorubicin, Cyclophosphamide - Breast Neoplasm | Phase 2 | Completed | Merck Sharp & Dohme LLC | 70 | 2003-03-01 | 2015-09-30 |
| Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer Vinorelbine, Capecitabine - Breast Neoplasm | Phase 2 | Completed | University of Washington | 40 | 2002-05-01 | 2012-09-13 |
| Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12 Paclitaxel, Doxorubicin, Cyclophosphamide - Breast Neoplasm | Phase 2 | Completed | University of Washington | 80 | 2001-12-01 | 2012-09-13 |
Showing 20 of 24. Sign in to see all of them.
Breast Neoplasms (24) · Neoplasm Metastasis (3) · Neoplasms (3) · Anxiety Disorders (1) · Carcinoma, Non-Small-Cell Lung (1) · Fatigue (1) · Ketosis (1) · Melanoma (1) · Triple Negative Breast Neoplasms (1)
Breast Diseases (24) · Neoplasms by Site (24) · Skin Diseases (24) · Skin and Connective Tissue Diseases (24) · Neoplasms (21) · Pathological Conditions, Signs and Symptoms (4) · Neoplastic Processes (3) · Pathologic Processes (3) · Acid-Base Imbalance (1) · Acidosis (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1) · Lung Neoplasms (1) · Mental Disorders (1)
Cyclophosphamide (7) · Docetaxel (4) · Capecitabine (3) · Doxorubicin (3) · Trastuzumab (3) · Granulocyte Colony-Stimulating Factor (2) · Letrozole (2) · Paclitaxel (2) · Tamoxifen (2) · Vinorelbine (2) · eribulin (2) · liposomal doxorubicin (2) · 1-dodecylpyridoxal (1) · Anastrozole (1) · Aromatase Inhibitors (1)
Merck Sharp & Dohme LLC (4) · University of Washington (3) · BriaCell Therapeutics Corporation (2) · National Cancer Institute (NCI) (2) · Accelerated Community Oncology Research Network (1) · Bayer (1) · Borstkanker Onderzoek Groep (1) · Eisai Inc. (1) · Evgen Pharma (1) · Hope Rugo, MD (1) · MedSIR (1) · Merck KGaA, Darmstadt, Germany (1) · Norwegian Breast Cancer Group (1) · Novartis Pharmaceuticals (1) · Peng Yuan (1)
United States (14) · Spain (4) · Belgium (3) · United Kingdom (3) · Austria (2) · Canada (2) · France (2) · Germany (2) · Italy (2) · Australia (1) · China (1) · Ireland (1) · Israel (1) · Netherlands (1) · New Zealand (1)
George E Peoples, MD, FACS (2) · Georgiana K. Ellis, M.D. (2) · A. Elise van Leeuwen-Stok, PhD (1) · Antonio Llombart, MD (1) · Dr. Claudio Savulsky (1) · Erik Wist, MD, PhD (1) · Geraldine Jacobson, MD MPH (1) · Hope Rugo, M.D. (1) · JoAnne Zujewski, M.D. (1) · Julie R. Gralow, M.D. (1) · Lee S Schwartzberg, MD, FACP (1) · Lisle Nabell, M.D. (1)
PMID 15501952, PMID 19380449, PMID 19767314, PMID 19858391, PMID 20012355, PMID 20697802, PMID 22056854, PMID 22248721, PMID 40017682